Comparing α-blockers and mirabegron for treating ureteral stones
Author Information
Author(s): Yan Huilei, Li Xiaoni, Zheng Xiaobo, Cui Yuanshan, Huang Jing, Cheng Yan
Primary Institution: Liaocheng People’s Hospital, Liaocheng, China
Hypothesis
This meta-analysis evaluates the safety and effectiveness of α-blockers versus mirabegron in treating ureteral calculi.
Conclusion
The study found that α-blockers significantly improve stone expulsion rates compared to mirabegron, but are associated with a higher risk of adverse events.
Supporting Evidence
- The meta-analysis included six publications with 592 patients.
- The α-blocker group had a significantly higher stone expulsion rate than the mirabegron group.
- Adverse events were more common in the α-blocker group, including orthostatic hypotension and headache.
- No serious adverse effects were reported in any of the RCTs.
- Statistical analysis showed significant differences in stone expulsion rates.
- All included studies were randomized controlled trials.
Takeaway
This study shows that one type of medicine helps people pass kidney stones better than another, but it can also cause more side effects.
Methodology
A systematic review and meta-analysis of randomized controlled trials comparing α-blockers and mirabegron for ureteral calculi.
Potential Biases
The included studies exhibited a low risk of bias.
Limitations
The analysis was limited to five RCTs, and there was heterogeneity in stone characteristics and treatment protocols.
Participant Demographics
Participants had unilateral ureter stones sized between 4 and 10 mm.
Statistical Information
P-Value
0.03
Confidence Interval
95% CI: 1.05 to 2.16
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website